199 related articles for article (PubMed ID: 38057283)
1. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
2. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
3. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
5. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract][Full Text] [Related]
6. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
Xiaoxu D; Min X; Chengcheng C
BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of
Yin X; Li J; Chen B; Liu K; Hu S
Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
9. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
[TBL] [Abstract][Full Text] [Related]
10. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Correlation and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Radiomics-Clinical Integration Approach.
Li K; Ji J; Li S; Yang M; Che Y; Xu Z; Zhang Y; Wang M; Fang Z; Luo L; Wu C; Lai X; Dong J; Zhang X; Zhao N; Liu Y; Wang W
J Magn Reson Imaging; 2024 Apr; 59(4):1206-1217. PubMed ID: 37526043
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
15. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y
Front Immunol; 2022; 13():868155. PubMed ID: 35664009
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
18. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
[TBL] [Abstract][Full Text] [Related]
20. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
Wakasu S; Tagawa T; Haratake N; Kinoshita F; Oku Y; Ono Y; Takenaka T; Oda Y; Shimokawa M; Mori M
Cancer Immunol Immunother; 2023 Jun; 72(6):1823-1834. PubMed ID: 36688996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]